RUNX2 and acute myeloid leukemia: Consistent with these findings in mouse LSCs, the PI3K inhibitor copanlisib also induced myeloid differentiation in the human AML cell lines MOLM14, NOMO1 and OCI-AML3, as evidenced by changes in morphology and increased expression of the monocytic markers CD15 and CD11b (Supplementary Figure 2).